ETF Holdings Breakdown of FOLD

Stock NameAmicus Therapeutics Inc
TickerFOLD(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS03152W1099
LEI549300MRD1SMUTNBPQ53

News associated with FOLD

Amicus Therapeutics' Pombiliti+Opfolda Receives Japan MHLW's Approval For Pompe Treatment
(RTTNews) - Amicus Therapeutics, Inc. (FOLD), Wednesday announced that Japan's Ministry of Health, Labour and Welfare or MHLW has approved the combination therapy of Pombiliti and Opfolda for the treatment of adult patients with late-onset Pompe disease, an inherited lysosomal di - 2025-06-25 11:47:15
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Consensus PT from Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokers […] - 2025-06-17 06:08:53
Millennium Management LLC Has $4.31 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Millennium Management LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 10.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 457,014 shares of the biopharmaceutical company’s stock after buying an additional 44,449 shares during the period. Millennium Management LLC’s holdings in Amicus Therapeutics were worth $4,305,000 at the end […] - 2025-05-30 08:39:05
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Man Group plc
Man Group plc lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 92.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,441 shares of the biopharmaceutical company’s stock after selling 680,887 shares during the quarter. Man Group plc’s holdings in Amicus […] - 2025-05-26 07:59:00
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.22
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average […] - 2025-05-23 06:14:52
Nuveen Asset Management LLC Buys 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Nuveen Asset Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,807,420 shares of the biopharmaceutical company’s stock after buying an additional 159,139 shares during the quarter. Nuveen Asset Management […] - 2025-05-21 08:10:52
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by BNP Paribas Financial Markets
BNP Paribas Financial Markets decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 14.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 484,560 shares of the biopharmaceutical company’s stock after selling 81,416 […] - 2025-05-14 09:11:00
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Jane Street Group LLC
Jane Street Group LLC lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 324,270 shares of the biopharmaceutical company’s stock after purchasing an additional 23,524 shares during the period. Jane […] - 2025-05-14 08:24:55
The Manufacturers Life Insurance Company Decreases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
The Manufacturers Life Insurance Company cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,788 shares of the biopharmaceutical company’s stock after selling 4,214 shares during the quarter. The Manufacturers […] - 2025-05-13 08:27:02
Amicus Therapeutics (NASDAQ:FOLD) Lowered to Hold Rating by StockNews.com
StockNews.com lowered shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a buy rating to a hold rating in a research note released on Monday. A number of other equities research analysts have also recently commented on FOLD. Wells Fargo & Company reduced their target price on shares of Amicus Therapeutics from $18.00 to $17.00 […] - 2025-05-06 05:36:47
Amicus Therapeutics (NASDAQ:FOLD) Given New $22.00 Price Target at UBS Group
Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its price target lifted by UBS Group from $21.00 to $22.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also recently weighed in on FOLD. Cantor Fitzgerald restated an “overweight” […] - 2025-05-05 07:25:01
CANADA LIFE ASSURANCE Co Has $753,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
CANADA LIFE ASSURANCE Co lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,076 shares of the biopharmaceutical company’s stock after acquiring an additional 5,522 […] - 2025-04-30 08:44:09
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Average Price Target from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […] - 2025-04-28 05:39:09
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legal & General Group Plc
Legal & General Group Plc decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 5.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 257,064 shares of the biopharmaceutical company’s stock after selling 15,329 shares during the quarter. […] - 2025-04-25 08:13:10
Russell Investments Group Ltd. Acquires 44,945 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Russell Investments Group Ltd. boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 539.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 53,282 shares of the biopharmaceutical company’s stock after acquiring an additional 44,945 shares during the quarter. Russell Investments Group Ltd.’s holdings in Amicus Therapeutics were worth $502,000 at […] - 2025-04-24 10:00:53
Alliancebernstein L.P. Sells 6,800 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Alliancebernstein L.P. lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 1.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 362,429 shares of the biopharmaceutical company’s stock after selling 6,800 shares during the period. Alliancebernstein L.P. owned 0.12% of […] - 2025-04-15 07:52:59
Orion Portfolio Solutions LLC Reduces Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Orion Portfolio Solutions LLC reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 8.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 84,693 shares of the biopharmaceutical company’s stock after selling 7,955 shares during the period. Orion Portfolio Solutions LLC’s holdings in Amicus Therapeutics were worth $798,000 as […] - 2025-04-07 08:34:53
Norges Bank Makes New $29.03 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Norges Bank bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 3,082,036 shares of the biopharmaceutical company’s stock, valued at approximately $29,033,000. A number of other hedge funds and other institutional investors have also made […] - 2025-04-07 07:51:12
Corebridge Financial Inc. Has $1.37 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Corebridge Financial Inc. lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 7.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,879 shares of the biopharmaceutical company’s stock after selling 11,011 shares during the quarter. Corebridge Financial Inc.’s holdings […] - 2025-04-04 08:40:54
KLP Kapitalforvaltning AS Purchases New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
KLP Kapitalforvaltning AS acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 49,000 shares of the biopharmaceutical company’s stock, valued at approximately $462,000. A number of other hedge funds also recently added to or […] - 2025-04-04 07:51:12
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Consensus PT from Analysts
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price […] - 2025-04-03 05:35:00
Cibc World Markets Corp Invests $259,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Cibc World Markets Corp purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 27,460 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. A number of other hedge funds have also bought and sold shares of FOLD. HealthInvest Partners AB […] - 2025-03-26 08:40:49
AlphaQuest LLC Buys 9,272 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
AlphaQuest LLC boosted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 635.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,732 shares of the biopharmaceutical company’s stock after purchasing an additional 9,272 shares during the quarter. AlphaQuest […] - 2025-03-19 08:46:47
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by US Bancorp DE
US Bancorp DE decreased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 59.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,884 shares of the biopharmaceutical company’s stock after selling 7,132 shares during the quarter. US Bancorp DE’s holdings in […] - 2025-03-19 07:10:47
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Assetmark Inc.
Assetmark Inc. reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 7.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,588 shares of the biopharmaceutical company’s stock after selling 8,499 shares during the quarter. Assetmark […] - 2025-03-12 07:58:58
Truist Financial Corp Has $168,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Truist Financial Corp decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 6.5% during the fourth quarter, HoldingsChannel reports. The firm owned 17,788 shares of the biopharmaceutical company’s stock after selling 1,235 shares during the quarter. Truist Financial Corp’s holdings in Amicus Therapeutics were worth $168,000 as of its most recent filing […] - 2025-03-07 08:30:49
Amicus Therapeutics (NASDAQ:FOLD) Lowered to “Hold” Rating by StockNews.com
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Thursday. A number of other research firms have also recently commented on FOLD. JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $16.00 […] - 2025-02-20 07:10:55

FOLD institutional holdings

The following institutional investment holdings of FOLD have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 149,537USD 850,866
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 20,150USD 114,654
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 153,846USD 875,384
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 153,846USD 875,384
2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,123USD 6,390
Total =478,502 USD 2,722,678
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.